Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner ; the mean ratio of day @ AUEC@-@ to day @ AUEC@-@ for dTT was @ with placebo , @ with @ g idarucizumab ( @ % reduction ) , @ with @ g idarucizumab ( @ % reduction ) , @ with @ g idarucizumab ( @ % reduction ) , and @ with @ g plus @ g idarucizumab ( @ % reduction ) .